Lung epithelial cells: Therapeutically inducible effectors of antimicrobial defense

Mucosal Immunology

Volumn 11, Issue 1, 2018, Pages 21-34

  Leiva Juarez M M ^a   Kolls, J K ^b   Evans, S E ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CATHELICIDIN; CHEMOKINE; COLLECTIN; DEFENSIN; IMMUNOSTIMULATING AGENT; LACTOFERRIN; LECTIN; LECTIN TYPE C; LYSOZYME; MEMBRANE PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NUCLEIC ACID SENSOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PLUNC PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

CELL JUNCTION; CYTOSKELETON; DOWN REGULATION; EPITHELIUM CELL; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFECTION RESISTANCE; INNATE IMMUNITY; ION TRANSPORT; LUNG EPITHELIUM; MUCOCILIARY CLEARANCE; MUCOSAL IMMUNITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETICS; IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; METABOLISM; RESPIRATORY MUCOSA; UPREGULATION;

ANIMALS; ANTI-INFECTIVE AGENTS; HUMANS; IMMUNE TOLERANCE; IMMUNITY; IMMUNOCOMPROMISED HOST; PNEUMONIA; RECEPTORS, PATTERN RECOGNITION; RESPIRATORY MUCOSA; UP-REGULATION;

EID: 85038866262     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2017.71     Document Type: Review

References (158)

1. Dickson, R.P. and Huffnagle, G.B. The lung microbiome: new principles for respiratory bacteriology in health and disease. PLoS Pathog. 11, e1004923 (2015).
2. Whitsett, J.A. and Alenghat, T. Respiratory epithelial cells orchestrate pulmonary innate immunity. Nat. Immunol. 16, 27-35 (2015).
3. Evans, S.E., Xu, Y., Tuvim, M.J. and Dickey, B.F. Inducible innate resistance of lung epithelium to infection. Annu. Rev. Physiol. 72, 413-435 (2010).
4. Franks, T.J. et al. Resident cellular components of the human lung: current knowledge and goals for research on cell phenotyping and function. Proc. Am. Thorac. Soc. 5, 763-766 (2008).
5. He, D. et al. Lysophosphatidic acid enhances pulmonary epithelial barrier integrity and protects endotoxin-induced epithelial barrier disruption and lung injury. J. Biol. Chem. 284, 24123-24132 (2009).
6. Wray, C. et al. Claudin-4 augments alveolar epithelial barrier function and is induced in acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L219-L227 (2009).
7. Davies, D.E. Epithelial barrier function and immunity in asthma. Ann. Am. Thorac. Soc. 11 (Suppl 5), S244-S251 (2014).
8. Brune, K., Frank, J., Schwingshackl, A., Finigan, J. and Sidhaye, V.K. Pulmonary epithelial barrier function: some new players and mechanisms. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L731-L745 (2015).
9. Ragupathy, S. et al. Toll-like receptor 2 regulates the barrier function of human bronchial epithelial monolayers through atypical protein kinase C zeta, and an increase in expression of claudin-1. Tissue Barriers 2, e29166 (2014).
10. Sancho, D. et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458, 899-903 (2009).
11. Mostowy, S. et al. Entrapment of intracytosolic bacteria by septin cage-like structures. Cell Host Microbe 8, 433-444 (2010).
12. Roy, M.G. et al. Muc5b is required for airway defence. Nature 505, 412-416 (2014).
13. Fahy, J.V. and Dickey, B.F. Airway mucus function and dysfunction. N. Engl. J. Med. 363, 2233-2247 (2010).
14. Kim, Y.D., Bae, C.H., Song, S.Y. and Choi, Y.S. Effect of b-glucan on MUC4 andMUC5Bexpression in human airway epithelial cells. Int. Forum Allergy Rhinol. 5, 708-715 (2015).
15. Fujisawa, T. et al. NF-kB mediates IL-1b-and IL-17 A-induced MUC5B expression in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 45, 246-252 (2011).
16. Voynow, J.A. and Rubin, B.K. Mucins, mucus, and sputum. Chest 135, 505-512 (2009).
17. Zhang, Y. et al. The human Cathelicidin LL-37 induces MUC5AC mucin production by airway epithelial cells via TACE-TGF-a-EGFR pathway. Exp. Lung Res. 40, 333-342 (2014).
18. Holtzman, M.J. et al. Immune pathways for translating viral infection into chronic airway disease. Adv. Immunol. 102, 245-276 (2009).
19. Barbier, D. et al. Influenza A induces the major secreted airway mucin MUC5AC in a protease-EGFR-extracellular regulated kinase-Sp1-dependent pathway. Am. J. Respir. Cell Mol. Biol. 47, 149-157 (2012).
20. Wlodarska, M. et al. NLRP6 inflammasome orchestrates the colonic hostmicrobial interface by regulating goblet cell mucus secretion. Cell 156, 1045-1059 (2014).
21. Hoegger, M.J. et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 345, 818-822 (2014).
22. Bonser, L.R., Zlock, L., Finkbeiner, W. and Erle, D.J. Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. J. Clin. Invest. 126, 2367-2371 (2016).
23. Roach, J.C. et al. The evolution of vertebrate Toll-like receptors. Proc. Natl Acad. Sci. USA 102, 9577-9582 (2005).
24. Burch-Smith, T.M. and Dinesh-Kumar, S.P. The functions of plant TIR domains. Sci. STKE 2007, pe46 (2007).
25. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J.M. and Hoffmann, J.A. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86, 973-983 (1996).
26. Gay, N.J., Symmons, M.F., Gangloff, M. and Bryant, C.E. Assembly and localization of Toll-like receptor signalling complexes. Nat. Rev. Immunol. 14, 546-558 (2014).
27. Botos, I., Segal, D.M. and Davies, D.R. The structural biology of Toll-like receptors. Structure 19, 447-459 (2011).
28. Chaput, C., Sander, L.E., Suttorp, N. and Opitz, B. NOD-like receptors in lung diseases. Front. Immunol. 4, 393 (2013).
29. Broz, P. and Monack, D.M. Newly described pattern recognition receptors team up against intracellular pathogens. Nat. Rev. Immunol. 13, 551-565 (2013).
30. Divangahi, M. et al. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J. Immunol. 181, 7157-7165 (2008).
31. Austin, C.M., Ma, X. and Graviss, E.A. Common nonsynonymous polymorphisms in the NOD2 gene are associated with resistance or susceptibility to tuberculosis disease in African Americans. J. Infect. Dis. 197, 1713-1716 (2008).
32. Chavarría-Smith, J. and Vance, R.E. Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor. PLoS Pathog. 9, e1003452 (2013).
33. De Nardo, D., De Nardo, C.M. and Latz, E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. Am. J. Pathol. 184, 42-54 (2014).
34. Kostadinova, E. et al. NLRP3 protects alveolar barrier integrity by an inflammasome-independent increase of epithelial cell adherence. Sci. Rep. 6, 30943 (2016).
35. Pétrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589 (2007).
36. Dostert, C. et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677 (2008).
37. Zhou, R., Yazdi, A.S., Menu, P. and Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
38. Berrington, W.R., Smith, K.D., Skerrett, S.J. and Hawn, T.R. Nucleotidebinding oligomerization domain containing-like receptor family, caspase recruitment domain (CARD) containing 4 (NLRC4) regulates intrapulmonary replication of aerosolized Legionella pneumophila. BMC Infect. Dis. 13, 371 (2013).
39. Tolle, L. et al. Redundant and cooperative interactions between TLR5 and NLRC4 in protective lung mucosal immunity against Pseudomonas aeruginosa. J. Innate Immun. 7, 177-186 (2015).
40. Schneider,M. et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kB. Nat. Immunol. 13, 823-831 (2012).
41. Sharma, S. and Fitzgerald, K.A. Innate immune sensing of DNA. PLoS Pathog. 7, e1001310 (2011).
42. Opitz, B., van Laak, V., Eitel, J. and Suttorp, N. Innate immune recognition in infectious and noninfectious diseases of the lung. Am. J. Respir.Crit. Care Med. 181, 1294-1309 (2010).
43. Bhoj, V.G. et al. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc. Natl Acad. Sci. USA 105, 14046-14051 (2008).
44. Foronjy, R.F. et al. Type-I interferons induce lung protease responses following respiratory syncytial virus infection via RIG-I-like receptors. Mucosal Immunol. 8, 161-175 (2015).
45. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
46. Ishikawa, H. and Barber, G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674-678 (2008).
47. Burdette, D.L. and Vance, R.E. STING and the innate immune response to nucleic acids in the cytosol. Nat. Immunol. 14, 19-26 (2013).
48. Unterholzner, L. et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 11, 997-1004 (2010).
49. Zhang, Z. et al. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat. Immunol. 12, 959-965 (2011).
50. Parvatiyar, K. et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat. Immunol. 13, 1155-1161 (2012).
51. Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826-830 (2013).
52. Yang, P. et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat. Immunol. 11, 487-494 (2010).
53. Geijtenbeek, T.B. and Gringhuis, S.I. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9, 465-479 (2009).
54. Heyl, K.A. et al. Dectin-1 is expressed in human lung and mediates the proinflammatory immune response to nontypeable Haemophilus influenzae. MBio 5, e01492-01414 (2014).
55. Drummond, R.A. and Lionakis, M.S. Mechanistic insights into the role of C-Type lectin receptor/CARD9 signaling in human antifungal immunity. Front. Cell. Infect. Microbiol. 6, 39 (2016).
56. Nayak, A., Dodagatta-Marri, E., Tsolaki, A.G. and Kishore, U. An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. Front. Immunol. 3, 131 (2012).
57. Evans, S.E. et al. Pneumocystis cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-kappaBdependent mechanisms. Am. J. Respir. Cell Mol. Biol. 32, 490-497 (2005).
58. Kolls, J.K., McCray, P.B. and Chan, Y.R. Cytokine-mediated regulation of antimicrobial proteins. Nat. Rev. Immunol. 8, 829-835 (2008).
59. Ganz, T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3, 710-720 (2003).
60. Lecaille, F., Lalmanach, G. and Andrault, P.M. Antimicrobial proteins and peptides in human lung diseases: a friend and foe partnership with host proteases. Biochimie 122, 151-168 (2015).
61. Frye,M. et al. Expression of human alpha-defensin 5 (HD5)mRNAin nasal and bronchial epithelial cells. J. Clin. Pathol. 53, 770-773 (2000).
62. Evans, S.E. et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am. J. Respir. Cell Mol. Biol. 42, 40-50 (2010).
63. Zanetti, M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75, 39-48 (2004).
64. Bals, R.,Wang, X., Zasloff, M.&Wilson, J.M. The peptide antibiotic LL-37/ hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl Acad. Sci. USA 95, 9541-9546 (1998).
65. Akiyama, T. et al. The human cathelicidin LL-37 host defense peptide upregulates tight junction-related proteins and increases human epidermal keratinocyte barrier function. J. Innate Immun. 6, 739-753 (2014).
66. De Yang, et al. LL-37, the neutrophil granule-and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192, 1069-1074 (2000).
67. Yang, D. et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286, 525-528 (1999).
68. Zhang, Z. et al. Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. Eur. J. Immunol. 39, 3181-3194 (2009).
69. Yu, J. et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J. Immunol. 179, 7684-7691 (2007).
70. Ganguly, D. et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 206, 1983-1994 (2009).
71. Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449, 564-569 (2007).
72. Mookherjee, N. et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 176, 2455-2464 (2006).
73. Williams, S.E., Brown, T.I., Roghanian, A. and Sallenave, J.M. SLPI and elafin: one glove, many fingers. Clin. Sci. (Lond.) 110, 21-35 (2006).
74. Tomee, J.F., Hiemstra, P.S., Heinzel-Wieland, R. and Kauffman, H.F. Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. J. Infect. Dis. 176, 740-747 (1997).
75. Hiemstra, P.S. et al. Antibacterial activity of antileukoprotease. Infect. Immun. 64, 4520-4524 (1996).
76. Simpson, A.J., Maxwell, A.I., Govan, J.R., Haslett, C. and Sallenave, J.M. Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett. 452, 309-313 (1999).
77. Henriksen, P.A. et al. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J. Immunol. 172, 4535-4544 (2004).
78. Sano, C., Shimizu, T., Sato, K., Kawauchi, H. and Tomioka, H. Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages. Clin. Exp. Immunol. 121, 77-85 (2000).
79. van Bergen, B.H., Andriessen, M.P., Spruijt, K.I., van de Kerkhof, P.C. and Schalkwijk, J. Expression of SKALP/elafin during wound healing in human skin. Arch. Dermatol. Res. 288, 458-462 (1996).
80. Margulieux, K.R., Fox, J.W., Nakamoto, R.K. and Hughes, M.A. CXCL10 acts as a bifunctional antimicrobial molecule against Bacillus anthracis. MBio 7, (2016).
81. Cole, A.M. et al. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J. Immunol. 167, 623-627 (2001).
82. Dai, C. et al. CXCL14 displays antimicrobial activity against respiratory tract bacteria and contributes to clearance of Streptococcus pneumoniae pulmonary infection. J. Immunol. 194, 5980-5989 (2015).
83. Dajani, R. et al. Lysozyme secretion by submucosal glands protects the airway from bacterial infection. Am. J. Respir. Cell Mol. Biol. 32, 548-552 (2005).
84. Akinbi, H.T., Epaud, R., Bhatt, H. and Weaver, T.E. Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. J. Immunol. 165, 5760-5766 (2000).
85. Ellison, R.T. 3rd&Giehl, T.J. Killing of gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 88, 1080-1091 (1991).
86. Flo, T.H. et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432, 917-921 (2004).
87. Chan, Y.R. et al. Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J. Immunol. 182, 4947-4956 (2009).
88. Aujla, S.J. et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 14, 275-281 (2008).
89. Crouch, E.C. Collectins and pulmonary host defense. Am. Respir. Cell. Mol. Biol. 19, 177-201 (1998).
90. LeVine, A.M. and Whitsett, J.A. Pulmonary collectins and innate host defense of the lung. Microbes Infect. 3, 161-166 (2001).
91. Wu, H. et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J. Clin. Invest 111, 1589-1602 (2003).
92. Thaikoottathil, J. and Chu, H.W. MAPK/AP-1 activation mediates TLR2 agonist-induced SPLUNC1 expression in human lung epithelial cells. Mol Immunol 49, 415-422 (2011).
93. Bingle, C.D. and Gorr, S.U. Host defense in oral and airway epithelia: chromosome 20 contributes a new protein family. Int. J. Biochem. Cell Biol. 36, 2144-2152 (2004).
94. Liu, Y. et al. Increased susceptibility to pulmonary Pseudomonas infection in Splunc1 knockout mice. J. Immunol. 191, 4259-4268 (2013).
95. Liu, Y. et al. SPLUNC1/BPIFA1 contributes to pulmonary host defense against Klebsiella pneumoniae respiratory infection. Am. J. Pathol. 182, 1519-1531 (2013).
96. Fischer, H. Mechanisms and function of DUOX in epithelia of the lung. Antioxid. Redox Signal. 11, 2453-2465 (2009).
97. Forteza, R., Salathe, M., Miot, F. and Conner, G.E. Regulated hydrogen peroxide production by Duox in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 32, 462-469 (2005).
98. Pezzulo, A.A. et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487, 109-113 (2012).
99. Chandler, J.D. and Day, B.J. Biochemical mechanisms and therapeutic potential of pseudohalide thiocyanate in human health. Free Radic. Res. 49, 695-710 (2015).
100. Hammad, H. et al. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat. Med. 15, 410-416 (2009).
101. Allakhverdi, Z. et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 204, 253-258 (2007).
102. Llop-Guevara, A. et al. A GM-CSF/IL-33 pathway facilitates allergic airway responses to sub-threshold house dust mite exposure. PLoS One 9, e88714 (2014).
103. O'Grady, S.M. et al. ATPrelease and Ca2+ signalling by human bronchial epithelial cells following Alternaria aeroallergen exposure. J. Physiol. 591, 4595-4609 (2013).
104. Kool, M. et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 34, 527-540 (2011).
105. Dulek, D.E. et al. Allergic airway inflammation decreases lung bacterial burden following acute Klebsiella pneumoniae infection in a neutrophiland CCL8-dependent manner. Infect. Immun. 82, 3723-3739 (2014).
106. Sharma, M., Sharma, S., Roy, S., Varma, S. and Bose, M. Pulmonary epithelial cells are a source of interferon-gamma in response to Mycobacterium tuberculosis infection. Immunol. Cell Biol. 85, 229-237 (2007).
107. Murdock, B.J., Huffnagle, G.B., Olszewski, M.A. and Osterholzer, J.J. Interleukin-17 A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production. Infect. Immun. 82, 937-948 (2014).
108. Lee, H.S. et al. IL-23 secreted by bronchial epithelial cells contributes to allergic sensitization in asthma model: role of IL-23 secreted by bronchial epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 312, L13-L21 (2017).
109. Spolski, R. and Leonard, W.J. Interleukin-21: a double-edged sword with therapeutic potential. Nat. Rev. Drug Discov. 13, 379-395 (2014).
110. Di Stefano, A. et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin. Exp. Immunol. 157, 316-324 (2009).
111. Ouyang,W., Kolls, J.K. and Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28, 454-467 (2008).
112. Schneider, D.S. and Ayres, J.S. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat. Rev. Immunol. 8, 889-895 (2008).
113. Westphalen, K. et al. Sessile alveolar macrophages communicate with alveolar epithelium to modulate immunity. Nature 506, 503-506 (2014).
114. Koga, T. et al. TNF-alpha induces MUC1 gene transcription in lung epithelial cells: its signaling pathway and biological implication. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L693-L701 (2007).
115. Ueno, K. et al. MUC1 mucin is a negative regulator of toll-like receptor signaling. Am. J. Respir. Cell. Mol. Biol. 38, 263-268 (2008).
116. Kim, K.C. and Lillehoj, E.P. MUC1 mucin: a peacemaker in the lung. Am. J. Respir. Cell. Mol. Biol. 39, 644-647 (2008).
117. Lu, W. et al. Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa byMuc1 knockout mice. J. Immunol. 176, 3890-3894 (2006).
118. Sawa, T. et al. Evaluation of antimicrobial and lipopolysaccharideneutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob. Agents Chemother. 42, 3269-3275 (1998).
119. Tecle, T., White, M.R., Gantz, D., Crouch, E.C. and Hartshorn, K.L. Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses. J. Immunol. 178, 8046-8052 (2007).
120. Uddin, M. and Levy, B.D. Resolvins: natural agonists for resolution of pulmonary inflammation. Prog. Lipid Res. 50, 75-88 (2011).
121. Levy, B.D. and Serhan, C.N. Resolution of acute inflammation in the lung. Annu. Rev. Physiol. 76, 467-492 (2014).
122. Clement, C.G. et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 177, 1322-1330 (2008).
123. Duggan, J.M. et al. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J. Immunol. 186, 5916-5926 (2011).
124. Yu, F.S. et al. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J. Immunol. 185, 1142-1149 (2010).
125. Wu, C.C. et al. Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand. J. Innate Immun. 6, 315-324 (2014).
126. Wu, C.C. et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc. Natl Acad. Sci. USA 104, 3990-3995 (2007).
127. Davis, C.G. et al. TLR3 agonist improves survival to secondary pneumonia in a double injury model. J. Surg. Res. 182, 270-276 (2013).
128. Pyles, R.B., Jezek, G.E. and Eaves-Pyles, T.D. Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect. Immun. 78, 1700-1710 (2010).
129. Hammerbeck, D.M. et al. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res. 73, 1-11 (2007).
130. Wu,C.C. et al. In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model. Cell. Immunol. 251, 78-85 (2008).
131. Lembo, A. et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J. Immunol. 180, 7574-7581 (2008).
132. Tuvim, M.J., Gilbert, B.E., Dickey, B.F. and Evans, S.E. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One 7, e30596 (2012).
133. Leiva-Juarez, M.M. et al. Inducible epithelial resistance protects mice against leukemia-associated pneumonia. Blood 128, 982-992 (2016).
134. Cleaver, J.O. et al. Lung epithelial cells are essential effectors of inducible resistance to pneumonia. Mucosal Immunol. 7, 78-88 (2014).
135. Goulet, M.L. et al. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog. 9, e1003298 (2013).
136. Shirey, K.A. et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497, 498-502 (2013).
137. Morales-Nebreda, L., Mutlu, G.M., Scott Budinger, G.R. and Radigan, K.A. Loss of TLR4 does not prevent influenza A-induced mortality. Am. J. Respir. Crit. Care Med. 189, 1280-1281 (2014).
138. Beljanski, V. et al. Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. J. Virol. 89, 10612-10624 (2015).
139. Chiang, C. et al. Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J. Virol. 89, 8011-8025 (2015).
140. Rivas-Santiago, B. et al. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 41, 143-148 (2013).
141. Bowdish, D.M., Davidson, D.J., Scott, M.G. and Hancock, R.E. Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chemother. 49, 1727-1732 (2005).
142. Beaumont, P.E. et al. Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo. PLoS One 9, e99029 (2014).
143. Kurosaka, K., Chen, Q., Yarovinsky, F., Oppenheim, J.J. and Yang, D. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. 174, 6257-6265 (2005).
144. Shu, Q. et al. Protection against Pseudomonas aeruginosa pneumonia and sepsis-induced lung injury by overexpression of beta-defensin-2 in rats. Shock 26, 365-371 (2006).
145. Rivas-Santiago, C.E., Rivas-Santiago, B., León, D.A., Castaneda-Delgado, J. and Hernández Pando, R. Induction of b-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis. Clin. Exp. Immunol. 164, 80-89 (2011).
146. Song, Z. et al. Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob. Agents Chemother. 49, 3868-3874 (2005).
147. Mukherjee, S. et al. Antibacterial membrane attack by a pore-forming intestinal C-type lectin. Nature 505, 103-107 (2014).
148. Choi, S.M. et al. Innate Stat3-mediated induction of the antimicrobial protein Reg3g is required for host defense against MRSA pneumonia. J. Exp. Med. 210, 551-561 (2013).
149. Chandler, J.D., Min, E., Huang, J., Nichols, D.P. and Day, B.J. Nebulized thiocyanate improves lung infection outcomes in mice. Br. J. Pharmacol. 169, 1166-1177 (2013).
150. Fischer, A.J. et al. Enhancement of respiratory mucosal antiviral defenses by the oxidationof iodide.Am. J.Respir.Cell.Mol.Biol. 45, 874-881 (2011).
151. Abou Alaiwa, M.H. et al. Repurposing tromethamine as inhaled therapy to treat CF airway disease. JCI Insight 12016).
152. Heltshe, S.L. et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin. Infect. Dis. 60, 703-712 (2015).
153. Rowe, S.M. et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am. J. Respir. Crit. Care Med. 190, 175-184 (2014).
154. Burdelya, L.G. et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320, 226-230 (2008).
155. Alfaro, V.Y. et al. Safety, tolerability, and biomarkers of the treatment of mice with aerosolized Toll-like receptor ligands. Front. Pharmacol. 5, 8 (2014).
156. Porte, R. et al. A toll-like receptor 5 agonist improves the efficacy of antibiotics in treatment of primary and influenza virus-associated pneumococcal mouse infections. Antimicrob. Agents Chemother. 59, 6064-6072 (2015).
157. Deng, J.C. et al. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J. Immunol. 173, 5148-5155 (2004).
158. Currie, S.M. et al. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One 8, e73659 (2013).